DCAF10

Across TCGA pan-cancer cohorts, DCAF10 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DCAF10 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DCAF10 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DCAF10 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LUAD, BRCA, and MESO are the cancer types where DCAF10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.171	0.835	<.001	24	view →
BRCA	OS	Median	All	0.746	0.963	.019	14	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SARC	OS	Median	All	0.281	0.745	.046	3	view →
BLCA	DFS	Median	All	1.000	0.330	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DCAF10–LUAD (OS)

Open the LUAD breakdown →